Leerink Partners Assumes Contineum Therapeutics (CTNM) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CTNM Hot Sheet
Price: $9.62 -0.72%
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Leerink Partners analyst Roanna Ruiz assumes coverage on Contineum Therapeutics (NASDAQ: CTNM) with a Outperform rating and a price target of $22.00.
For an analyst ratings summary and ratings history on Contineum Therapeutics click here. For more ratings news on Contineum Therapeutics click here.
Shares of Contineum Therapeutics closed at $11.47 yesterday.
You May Also Be Interested In
- Contineum Therapeutics (CTNM) PT Lowered to $23 at Stifel
- Freedom Broker Starts Dole (DOLE) at Buy
- Freedom Broker Starts Del Monte (DMC) at Hold
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
